US Department of Health and Human Services: Healthy People 2010, 2nd Ed, US Government Printing Office, Washington, DC, November. 2000. .
Centers for Medicare and Medicaid Services: Decision Memorandum for Diabetic Peripheral Neuropathy with Loss of Protective Sensation (LOPS) (CAG-00059), Centers for Medicare and Medicaid Services, Baltimore, October. 2001. .
Bild DE, Selby JV, Sinnock JA: Lower extremity amputation in people with diabetes: epidemiology and prevention. .Diabetes Care12::24. ,1989. .
Mayfield JA, Sugarman JR: The use of the Semmes-Weinstein monofilament and other threshold tests for preventing foot ulceration and amputation in persons with diabetes. .J Fam Pract49::S17. ,2000. .11093555)| false
The medical records of 1,047 patients (mean age, 73 years) with established peripheral neuropathy were examined to determine whether treatment with monochromatic infrared photo energy was associated with increased foot sensitivity to the 5.07 Semmes-Weinstein monofilament. The peripheral neuropathy in 790 of these patients (75%) was due to diabetes mellitus. Before treatment with monochromatic infrared photo energy, of the ten tested sites (five on each foot), a mean ± SD of 7.9 ± 2.4 sites were insensitive to the 5.07 Semmes-Weinstein monofilament, and 1,033 patients exhibited loss of protective sensation. After treatment, the mean ± SD number of insensate sites on both feet was 2.3 ± 2.4, an improvement of 71%. Only 453 of 1,033 patients (43.9%) continued to have loss of protective sensation after treatment. Therefore, monochromatic infrared photo energy treatment seems to be associated with significant clinical improvement in foot sensation in patients, primarily Medicare aged, with peripheral neuropathy. Because insensitivity to the 5.07 Semmes-Weinstein monofilament has been reported to be a major risk factor for diabetic foot wounds, the use of monochromatic infrared photo energy may be associated with a reduced incidence of diabetic foot wounds and amputations. (J Am Podiatr Med Assoc 95(2): 143–147, 2005)
Corresponding author: Thomas J. Burke, PhD, Director of Research and Clinical Affairs, Anodyne Therapy LLC, 13570 Wright Cir, Tampa, FL 33626.